Login to Your Account



Celsion rises on early GEN-1 immunotherapy data in ovarian cancer

By Michael Fitzhugh
Staff Writer

Saturday, February 21, 2015

Early positive data supporting Celsion Corp.'s plans to further develop its interleukin-12 (IL-12)-producing immunotherapy, GEN-1, for the treatment of advanced platinum-resistant and recurrent ovarian cancer boosted shares (NASDAQ:CLSN) by 12.9 percent to $3.15 at Friday's close, providing early validation for its $14 million cash- and share-based acquisition of Huntsville, Ala.-based Egen Inc.'s nucleic acid-based therapeutic assets.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription